Private Hospital Group in Spain Expands Radiotherapy Capabilities with Country's First Elekta Versa HD System

    Private Hospital Group in Spain Expands Radiotherapy Capabilities with
                    Country's First Elekta Versa HD System

PR Newswire

MADRID, Oct. 24, 2013

MADRID, Oct. 24, 2013 /PRNewswire/ --HM Hospitales, a private hospital group
in Spain, anticipates treating its first patients with Elekta's Versa HD™
system in 2015. Versa HD, to be sited in the group's sixth hospital, isan
advanced radiation treatment system designed to enhance the management of
cancer care and treat a broad spectrum of tumors throughout the body. The most
sophisticated linear accelerator on the market, Elekta's Versa HD is a single
system capable of delivering conventional therapies for an expansive range of
indications commonly seen in the clinic, while also permitting treatment of
complex cancers that require exceptional targeting accuracy.

"Versa HD will allow us to treat patients with the most modern radiation
therapy techniques, from traditional treatments to radiosurgery procedures,"
says Juan Abarca Cidon, M.D., general manager of HM Hospitales. "We will use
Versa HD for virtually all cancer pathologies located throughout the body. The
system's High Dose Rate mode and ultra-fast and precise Agility™ beam shaping
capabilities also will improve the speed with which we can deliver therapy,
which will improve patient comfort through shorter treatment times."

The new medical center, Hospital HM Universitario Puerto del Sur, will be
connected to the hospital group's first radiation oncology department – Clara
Campal Comprehensive Cancer Center at HM Sanchinarro – via Elekta's MOSAIQ®
Oncology Information System (OIS). MOSAIQ replaces the Siemens LANTIS OIS that
had been in use at the cancer center.

"The Puerto del Sur clinic will serve an area of approximately one million
inhabitants in the area south of Madrid," Dr. Cidon says. "It is important
that we provide cancer patients in Mostoles and the wider region with access
to the very latest treatment technology."

For more information, visit www.VersaHD.com.

Versa HD is not for sale or distribution in all markets.

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.andersson@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management,
Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow
enhancing software systems across the spectrum of cancer care. Stretching the
boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare
providers and patients, Elekta aims to improve, prolong and even save patient
lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,500 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker STO:EKTAB. Website:
www.elekta.com.

SOURCE Elekta

Website: http://www.elekta.com
 
Press spacebar to pause and continue. Press esc to stop.